Materials and methods I conducted the project using Plan, Do, Study, Act quality
improvement methodology: a driver diagram was created; outcome and process measures …

Abstract Background Apixaban (ELIQUIS®) is a direct oral anticoagulant authorised for
multiple indications in the European Economic Area (EEA). Additional risk minimisation …

Background: Direct Oral Anticoagulants (DOACs) are used as an alternative to Warfarin for
prevention and treatment of stroke, pulmonary embolism and deep vein thrombosis …

Objectives: Identify the appropriate indications for apixaban. Summarize the mechanism of
action of apixaban. Describe the potential adverse event profile of apixaban. Review …

Purpose To increase patient knowledge about apixaban (Eliquis, Bristol-Myers Squibb)
using an educational video delivered in an urban inpatient setting. Methods This …

Purpose To estimate the proportion of apixaban users who received the drug for on‐label
indications and characterise the patients using apixaban for on‐label and off‐label …

Introduction: Little is known about the potential safety issues associated with apixaban in
clinical practice and their reporting in spontaneous adverse event (SAE) databases …

Abstract Introduction: Directoral anticoagulants (DOACs) are favoured over oral vitamin K
antagonists (VKA) due to their fixed-dose regimen and reduced thromboembolic and …

Background: Apixaban is a direct oral anticoagulant, which inhibits factor Xa. It has
demonstrated clinical efficacy in prevention of stroke and systemic embolism in adult …

Aim To assess pharmacokinetic and pharmacodynamic interactions between naproxen (a
non‐steroidal anti‐inflammatory drug) and apixaban (an oral, selective, direct factor‐X a …